Treatment of rosacea

Area of Science:

• Dermatology
• Microbiology

Background:

• Rosacea treatment encompasses various topical and oral agents, including antibiotics, retinoids, and azelaic acid.
• Systemic therapy is sometimes preferred due to skin sensitivity to topical irritants.
• Isotretinoin is reserved for severe, treatment-resistant rosacea cases.

Purpose of the Study:

• To review current rosacea treatment options and their evidence base.
• To highlight the need for high-quality randomized controlled trials in rosacea research.
• To present a clinical practice approach incorporating trigger identification and targeted therapies.

Main Methods:

• Review of existing literature and a recent Cochrane review on rosacea treatments.
• Clinical evaluation for potential triggers: Helicobacter pylori infection and small intestinal bacterial overgrowth (SIBO).
• Assessment for Demodex folliculorum infestation and targeted treatment when concentrations exceed 5/cm(2).

Main Results:

• Topical metronidazole, azelaic acid, and low-dose oral doxycycline show some evidence for moderate to severe rosacea.
• Many existing studies on rosacea treatments have a high or unclear risk of bias.
• Clinical practice involves assessing H. pylori and SIBO, using oral antibiotics (metronidazole, tetracycline) for papulopustular rosacea, and topical treatments for Demodex.

Conclusions:

• Evidence for many rosacea treatments is limited, necessitating further robust clinical trials.
• Identifying and treating underlying triggers like H. pylori, SIBO, and Demodex infestation is a key component of effective rosacea management.
• A tailored approach combining trigger-targeted therapies and standard treatments may improve outcomes for papulopustular rosacea.